FDA Panel Says Columbia Labs' (CBRX) Data on Preterm Birth Gel Isn't Sufficient (WPI)
FDA panel votes 13-4 data on Columbia Labs' (Nasdaq: CBRX) is not sufficent on preterm birth gel.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Angelo, Gordon to Acquire Benihana (BNHN) for $16.30/Share in Cash
- MediciNova (MNOV) trading halted with news pending
- Jeffersonville Bancorp (JFBC) to Voluntarily Delist from NASDAQ
Create E-mail Alert Related Categories
FDA, Hot FDA News, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
